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effectiveness of hepatitis A vaccination programs in the United States.
Methods: We developed an age-structured population model of hepatitis
A transmission dynamics to evaluate two policies of administering a two-
dose hepatitis A vaccine to children aged 12 to 18 months: 1) universal
routine vaccination as recommended by the Advisory Committee on
Immunization Practices in 2006 and 2) Advisory Committee on Immuni-
zation Practices’s previous regional policy of routine vaccination of
children living in states with high hepatitis A incidence. Inputs were
obtained from the published literature, public sources, and clinical trial
data. The model was ﬁtted to hepatitis A seroprevalence (National Health
and Nutrition Examination Survey II and III) and reported incidence from
the National Notiﬁable Diseases Surveillance System (1980–1995). We
used a societal perspective and projected costs (in 2013 US $), quality-
adjusted life-years, incremental cost-effectiveness ratio, and other out-
comes over the period 2006 to 2106. Results: On average, universal
routine hepatitis A vaccination prevented 259,776 additional infections,
167,094 outpatient visits, 4781 hospitalizations, and 228 deaths annually.ee front matter Copyright & 2015, International S
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ndence to: Elamin H. Elbasha, Merck Research LabCompared with the regional vaccination policy, universal routine hepatitis
A vaccination was cost saving. In scenario analysis, universal vaccination
prevented 94,957 infections, 46,179 outpatient visits, 1286 hospitalizations,
and 15 deaths annually and had an incremental cost-effectiveness ratio of
$21,223/quality-adjusted life-year when herd protection was ignored.
Conclusions: Our model predicted that universal childhood hepatitis A
vaccination led to signiﬁcant reductions in hepatitis A mortality and
morbidity. Consequently, universal vaccination was cost saving compared
with a regional vaccination policy. Herd protection effects of hepatitis A
vaccination programs had a signiﬁcant impact on hepatitis A mortality,
morbidity, and cost-effectiveness ratios.
Keywords: cost-effectiveness analysis, hepatitis A vaccine, hepatitis A
virus, herd protection/immunity, simulation.
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Transmitted from person to person primarily through the fecal-
oral route, hepatitis A virus (HAV) is the principal etiological agent
of acute viral hepatitis, causing signiﬁcant morbidity worldwide
[1]. In the United States, hepatitis A was the most frequently
reported type of hepatitis during the 1980s and 1990s, with an
average of 26,000 cases reported annually [2]. Because not all cases
were symptomatic or reported, the actual number of infections
that occurred during this period was several times higher than the
reported number of cases (estimated at 270,000 infections per year
after correction for asymptomatic illness and underreporting) [3].
Although hepatitis A is usually a self-limiting disease, it can leadto several serious complications including fulminant liver failure
and death [4]. The HAV infection can also result in signiﬁcant
direct medical costs (from possible hospitalization), lost produc-
tivity (from absenteeism from work or school for possibly several
weeks or months), and additional costs associated with commun-
ity outbreaks (including infection control costs) [5–7].
There is no speciﬁc curative therapy for hepatitis A disease.
Management generally involves supportive care and medical
treatment of serious complications. Vaccines against HAV infec-
tion became available in the United States in 1995 and have been
recommended for use incrementally since then [8]. In 1996, the
Advisory Committee on Immunization Practices (ACIP) recom-
mended vaccinating persons at high risk of infection and childrenociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Flow diagram of hepatitis A virus transmission and vaccinationmodel: newborns enter age group a ¼ 0, and are assumed
to be protected by maternal antibodies (M), and the protection is lost over time so the children become susceptible (S). Upon
infection, a person moves to the exposed compartment (E) and becomes infectious after a latent period. The model distinguishes
between several categories of infection and disease: Asymptomatic (I); symptomatic infections are treated as outpatient (O),
hospitalized (H), with fulminant disease (F), requiring a liver transplant (L), or die from hepatitis A virus infection (D). Infected
persons can clear their infection and move to the recovered compartment (R) with lifelong immunity. The model also applied
age-speciﬁc all-cause mortality (not shown) to all persons in all epidemiologic classes.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 5 8 – 3 6 7 359living in communities at high risk [8]. In 1999, the recommenda-
tions were expanded to include children living in states, counties,
and communities with HAV rates higher than the national average
[8]. In 2006, the ACIP recommended routine vaccination for all
children aged 12 to 23 months in the United States [8]. Although
routine vaccination for all children is recommended, the uptake of
the two-dose hepatitis A vaccine is well below the coverage rates
of other pediatric and adolescent vaccines [9].
The low uptake of hepatitis A vaccine could be the main
reason for a signiﬁcant number of cases of HAV disease still
occurring in the United States. For example, 1670 cases of HAV
disease were reported in the United States. When adjusted for
underreporting and asymptomatic cases, an estimated 17,000
cases occurred in 2009 [10].
A number of studies assessed the cost-effectiveness of routine
or targeted hepatitis A vaccination in children or other risk
groups [11]. Using a cohort model, Rein et al. [12] showed that
universal hepatitis A vaccination of children in the United States
is a cost-effective strategy. Cohort models, however, do not
incorporate herd protection effects of vaccination. Using an
empirical approach relating hepatitis A vaccination coverage to
declines in hepatitis A incidence, one study showed that the
inclusion of herd protection effects due to vaccination has a
signiﬁcant impact on the estimates of disease outcomes and the
cost-effectiveness of hepatitis A vaccination [13].
It is well recognized that a more appropriate approach to
estimate the impact of herd protection and vaccination is to use a
dynamic model [14,15]. The aim of this study was to estimate the
public health and economic impact of a two-dose universal
hepatitis A vaccination program of children in the United States
for the period 2006 to 2106 using a dynamic disease transmission
model.Methods
Modeling Approach
We developed a deterministic, age-structured, epidemiologic
model to study the transmission of and vaccination against
HAV infection in the United States. The population was divided
into several distinct classes: maternal antibodies, susceptible,
exposed, asymptomatic infection, outpatient, hospitalized, ful-
minant, patients with recent liver transplant, patients with past
liver transplant, recovered, and vaccinated (Fig. 1). Each compart-
ment was further categorized into 110 age groups (0 to o1, 1, …,
and 109 years or older).
We chose a simple demographic model with an equilibrium
age distribution and a stationary population, where the number
of births is equal to the number of non–HAV-related deaths [16].
In the model, persons enter the population in the less-than-1-
year age group, and persons move between successive age groups
at an age-speciﬁc transfer rate per year. The transfer rate
depends on the mortality rate and the number of years spent
within an age group. Persons exit the model on death at an age-
speciﬁc death rate per year [16].
All infants are born with maternal antibodies. After immunity
derived from maternal antibodies wanes, infants move to the
susceptible class and remain there until they are vaccinated,
infected, or dead from causes other than HAV infection. A
fraction of susceptible persons are exposed to infection at an
age-speciﬁc and time-dependent rate (per capita force of infec-
tion) and enter the exposed compartment. The rate at which
persons of a given age class at a given time are exposed to
infection depends on the number of contacts, the fraction of
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 5 8 – 3 6 7360infected contacts, the transmission probability per contact, and
the nature of mixing between different age groups. The contact
pattern is governed by a conditional probability mixing matrix.
Each cell in the mixing matrix represents the probability of a
person of a given age class having contact with a person in
another age class.
After a latent period, exposed persons can become infectious.
Infection can be either asymptomatic or symptomatic. Patients
with symptoms are treated as outpatient or hospitalized, can
become fulminant, may require a liver transplant, or die from
HAV infection. To account for differential mortality, costs, and
quality of life during the period immediately after transplanta-
tion, we subdivided this health state into two: ﬁrst year and
subsequent years. Infected persons can clear their infection and
move to the recovered compartment with lifelong immunity.
Vaccinated persons leave the susceptible compartment at a given
vaccination rate and enter the vaccinated compartment and
remain there until they die or their immunity wanes.
The model used in the simulations consists of 1650 differential
equations corresponding to the 15 epidemiologic classes within
each of the 110 age groups. All differential equations and details of
the epidemiologic model are given in the Appendix in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.02.004.
Vaccination Strategies
Vaccination of persons aged 1 year or older against HAV infection
became available in the United States in 1995-1996. Before 2006,
the ACIP adopted an incremental vaccination strategy, focusing
primarily on vaccinating high-risk groups or children residing in
geographical locations with persistently high hepatitis A inci-
dence (termed regional vaccination policy in this study). In 2006,
the ACIP expanded the recommendations to include the routine
vaccination of children aged 1 year or more in the United States
(termed universal vaccination strategy in this study) [8].
In the model, the vaccination at age 1 year is incorporated by
moving a fraction of infants from the susceptible class to the
vaccination class before they are 2 years old. We compared hepatitis
A vaccination of children aged 1 year or older following a regional
strategy with routine vaccination using a universal strategy.
Model Parameters and Data Sources
We identiﬁed baseline values for demographic, epidemiologic,
vaccine, and economic inputs of the model through an extensive
search of the published literature (Table 1). The following
describes in brief the values and sources for key parameters.
Demographic Parameters
Death rates were obtained from US Decennial Life Tables for 1999
to 2001 for age-speciﬁc mortality rates across both sexes and all
races [17]. Other demographic data were obtained from the US
Census Bureau. For example, the US population in 2006 was
assumed to be 298,379,912 [18].
Transmission Rates and Force of Infection
Persons in the model could be infected either from foreign travel
or from coming in contact with an infected person living in the
United States. Analyses of data for the period before 1995
indicated that international travel accounted for only 4% of the
infections with a known source [19]. Recent estimates put
hepatitis A infections from travel to hepatitis A–endemic coun-
tries to be more than 45% of total infections [20]. To estimate the
force of infection for local transmission, we adjusted total
infection downward using estimates of age-speciﬁc contribution
of international travel to total transmission [21].The epidemiologic data on HAV infection suggest a behavior of
a dynamic system in transition [3]. To estimate the forces of
infection before vaccination programs were initiated, we used least
square methods to ﬁt the model to data on age-speciﬁc seropre-
valence from the National Health and Nutrition Examination
Survey II and III and reported incidence from the National Notiﬁ-
able Diseases Surveillance System (1980–1995) [22–24]. Because a
high proportion of hepatitis A infections are anicteric (i.e., are not
recognized) or reported, we divided the reported disease incidence
by the age-speciﬁc probability of developing jaundice and an
estimate of underreporting factor [3]. Our approach does not
assume that the endemic disease has reached an equilibrium state
before vaccination. Thus, the forces of infection continue to change
with time during the prevaccination period (Table 1). Assuming
proportionate mixing, we used the estimated age-speciﬁc force of
infection to calculate activity levels in the contact-mixing matrix
(see Appendix in Supplemental Materials). Other parameters of the
natural history of HAV infection are summarized in Table 1.
Hepatitis A Disease
Wemodeled several health outcomes associated with HAV infection
including outpatient visits, hospitalizations, fulminant disease, liver
transplant, and death (Fig. 1). The conditional probabilities given
symptomatic HAV infection were based on previous studies (Table 1).
We assumed that anicteric cases do not require health care and that
only the management of icteric hepatitis A cases entails the use of
health care resources. Furthermore, we assumed that all hospital-
izations including fulminant cases were reported to the public health
authorities. Thus, the conditional probabilities given in Table 1 were
divided by the underreporting factor to arrive at the probability of
hospitalization and fulminant disease given an icteric case [12].
Outpatient rates were estimated as a residual after accounting for
all other health outcomes among symptomatic patients.
Vaccine Parameters
Vaccine efﬁcacy for one or two doses was assumed to be 100%
[25]. Current data suggest that the duration of immunity con-
ferred by vaccination is long [26]. We assumed that the median
duration of protection of a completed one-dose and two-dose
hepatitis A vaccination in the base case was 21 and 32 years,
respectively, and examined alternative assumptions in sensitiv-
ity analyses [27]. We also assumed that one-dose vaccine cover-
age under the regional vaccination strategy stayed constant at
10% throughout the simulation period [28]. In the universal
vaccination strategy, we assumed that receipt of at least one
dose increased linearly from 60.4% in 2006 to 81.2% in 2011 and
then remained at 81.2% thereafter [29]. For both vaccination
strategies, we assumed that only 64.4% of the infants receiving
the ﬁrst dose will complete the two-dose vaccine series [29].
Costs
We adopted a societal perspective that requires the inclusion of
both direct and indirect costs. The direct costs included treatment
costs of HAV health outcomes and vaccination. Treatment costs
included costs for outpatient visits, hospitalizations, fulminant
disease, and liver transplantations [12,30,31]. For patients with
liver transplant, we included a recurring annual cost for the rest
of the patients’ lives in addition to the health care cost during the
year of the liver transplant. The vaccine costs included both the
public acquisition cost and the private market price [32]. In
particular, we used an average price, weighted by the market share
of public and private vaccine for hepatitis A [33]. Vaccine admin-
istration cost was assumed to be $14 per dose [34]. We subtracted a
$0.75 per dose Federal Excise Tax from total vaccine cost and did
not include costs associated with any potential adverse events.
Table 1 – Base-case estimates and corresponding distributions for deterministic and probabilistic sensitivity
analyses.
Parameter Base case Range Distribution Reference
Demography
Population in 2006 (thousands) 298,380 [17]
Age-speciﬁc all-cause mortality Varies [17]
Infection
Force of infection*
Scale parameter, b0 0.1021 Fixed Estimated
Shape parameter, b1 0.0001 Fixed Estimated
Shape parameter, b2 53.7928 Fixed Estimated
Shift parameter for last period before vaccination, Δ 0.4773 Fixed Estimated
Age-speciﬁc rate of exposure due to travel to endemic
countries (per year)
[21]
0–4 y 1.90  10–3 Fixed
5–9 y 8.06  10–4 Fixed
10–19 y 1.42  10–4 Fixed
20–29 y 8.89  10–5 Fixed
30–39 y 5.94  10–5 Fixed
40–59 y 1.76  10–5 Fixed
60þ y 1.80  10–5 Fixed
Duration of maternal immunity (mo) 6.5 Fixed [44]
Latency period (d) 14 Fixed [8,45]
Age-speciﬁc mean duration of infectiousness (wk) [21,46]
0–4 y 3.5 Fixed
5–9 y 3.0 Fixed
10þ y 2.5 Fixed
Vaccine
Vaccine efﬁcacy, one dose only (%) 100 87.3–100 Derived distribution† [25]
Vaccine efﬁcacy, two doses (%) 100 87.3–100 Derived distribution† Assumed
Median duration of vaccine-derived immunity, one dose
only (y)
21 20.3–21.9 Gamma (2647.1, 0.0079) Assumed
Median duration of vaccine-derived immunity, two doses
(y)
32 30.9–33.4 Gamma (2517.63, 0.0127) [27]
Vaccine uptake in 1995 and after, regional strategy, ﬁrst
dose (%)‡
10.0 1.8–17.0 Beta (5.88, 52.97) [47]
Vaccine uptake in 2006, universal strategy, ﬁrst dose (%)‡ 63.4 60.9–64.5 Beta (1743.69, 1006.61) [29]
Vaccine uptake in 2011 and after, universal strategy, ﬁrst
dose (%)
81.2 80.2–82.2 Beta (4761.11, 1102.33) [29]
Vaccine adherence, probability of second dose given ﬁrst
dose (%)
64.3 61.8–66.8 Beta (906.60, 503.35) [29]
Clinical outcomes
Underreporting factor 7.2870 Fixed Estimated
Probability an infection is icteric§ Varies [3]
Scale parameter, α0 0.852 Fixed
Shape parameter, α1 0.012 Fixed
Shape parameter, α2 1.903 Fixed
Probability of hospitalization of an icteric infection (%) [12]
r4 y 0.638 Dirichlet (D1)||
5–14 y 2.333 Dirichlet (D2)
15–39 y 3.088 Dirichlet (D3)
40–59 y 2.539 Dirichlet (D4)
60þ y 2.745 Dirichlet (D5)
Probability of fulminant hepatitis A from an icteric
infection (%)
[12]
r4 y 0.052 Dirichlet (D1)
5–14 y 0.007 Dirichlet (D2)
15–39 y 0.093 Dirichlet (D3)
40–59 y 0.755 Dirichlet (D4)
60þ y 1.098 Dirichlet (D5)
Probability of liver transplant from an icteric infection (%) [12]
r4 y 0.010 Dirichlet (D1)
5–14 y 0.001 Dirichlet (D2)
15–39 y 0.017 Dirichlet (D3)
continued on next page
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Table 1 – continued
Parameter Base case Range Distribution Reference
40–59 y 0.142 Dirichlet (D4)
60þ y 0.027 Dirichlet (D5)
Probability of death from an icteric infection (%) [12]
r4 y 0.008 Dirichlet (D1)
5–14 y 0.001 Dirichlet (D2)
15–39 y 0.014 Dirichlet (D3)
40–59 y 0.109 Dirichlet (D4)
60þ y 0.736 Dirichlet (D5)
Probability of death during ﬁrst year of liver
transplantation (%)
11.6 6.0–42.0 Beta (29.92, 228.02) [48]
Probability of death from year 2 and beyond after liver
transplantation (%)
4.4 2.4–11.0 Beta (4.63, 100.59) [48]
Duration of hepatitis A symptoms (d) [31]
Duration of outpatient icteric infection (d) 34.4 17–40 Gamma (34.37, 1.00)
Duration of inpatient icteric infection (d) 67.8 27–78 Gamma (27.16, 2.50)
Cost of one-dose vaccine (2013 $)
Public sector 15.25 [32]
Private market 30.369 [32]
Proportion purchased by public sector 0.56 [33]
Cost of vaccine administration (2013 $) 14 11–17 Gamma (83.66, 0.16) [34]
Medical costs (2013 $)
Outpatient cost 1,130 809–1,355 Gamma (66.05, 17.11) [12]
Hospitalization cost 11,165 6,360–22,841 Gamma (7.05, 1583.25) [12]
Fulminant cost 33,227 16,613– 49,840 Gamma (15.37, 2162.31) [12]
Annual cost of patients with liver transplant (ﬁrst year) 191,661 175,345–208,693 Gamma (507.37, 377.76) [30]
Annual cost of patients with liver transplant (subsequent
years)
43,203 35,161– 52,062 Gamma (100.24, 431.02) [30]
Public health cost of a reported infection (2013 $) 918 459–1,377 Gamma (15.37, 59.75) [12]
Productivity losses
Work loss, outpatient (d) 15.5 7–18 Gamma (1.95, 7.93) [31]
Work loss, inpatient (d) 33.2 10–25 Gamma (1.04, 31.70) [31]
Work loss, fulminant patient (d) 33.2 10–25 Gamma (1.04, 31.70) [31]
Work loss, year of transplant (d)
0–17 y 153.2 145–160 Gamma (1579.8, 0.09) [12]
18–40 y 245 238–253 Gamma (4064, 0.06) [49]
41–55 y 271 268–274 Gamma (36282, 0.007) [49]
56–62 y 288 284–291 Gamma (23050.5, 0.012) [49]
63þ y 314 306–321 Gamma (7389.12, 0.042) [49]
Labor force participation rate (%) [50]
16–19 y 34.3 33.5–35.0 Beta (5822.66, 11160.3)
20–24 y 70.9 70.3–71.5 Beta (15461.3, 6336.7)
25–34 y 81.7 81.3– 82.0 Beta (33464.2, 7509.8)
35–44 y 82.6 82.2– 82.9 Beta (32733.2, 6907.8)
45–54 y 80.2 79.8–80.6 Beta (35053.2, 8642.8)
55–64 y 64.5 64.0– 65.0 Beta (24709.4, 13606.6)
65þ y 18.5 18.0–18.8 Beta (7726.82, 34141.2)
Median weekly earnings (2013 $) [51,52]
16–24 y 452 6–1,230 Gamma (0.48, 931.86)
25–34 y 706 99–1,559 Gamma (1.18, 596.60)
35–44 y 868 206–1,733 Gamma (1.78, 485.25)
45–54 y 892 224–1,758 Gamma (1.89, 472.20)
55–64 y 907 235–1,773 Gamma (1.95, 464.39)
65þ y 825 175–1,688 Gamma (0.61, 510.54)
Discount rate per year (%) 3 0–5
Utilities
Average US population norms [39]
20–29 y 0.920 0.913–0.927 Beta (5307.70, 461.54)
30–39 y 0.905 0.898–0.912 Beta (6099.19, 640.25)
40–49 y 0.874 0.867–0.882 Beta (6572.42, 947.51)
50–59 y 0.848 0.840–0.857 Beta (5810.94, 1041.58)
60–69 y 0.824 0.812–0.836 Beta (3187.16, 680.75)
70–79 y 0.785 0.771–0.798 Beta (2791.9, 764.66)
continued on next page
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Table 1 – continued
Parameter Base case Range Distribution Reference
80þ y 0.744 0.720–0.768 Beta (944.35, 324.94)
Persons with anicteric hepatitis A 0.830 0.789–0.867 Beta (291.95,59.79) [12]
Persons with icteric hepatitis A 0.642 0.607–0.682 Beta (410.13, 228.31) [37]
Persons with liver transplant 0.730 0.630–0.840 Beta (49.40, 18.27) [38]
Discount rate per year (%) 3 0–5
* The force of infection at age group j is given by λn j¼Db0jb1 eðj=b2 Þ
† The distribution is given by 497249 248249 1Inversebetaregularized½1,Uniformð0,1Þ,25,1.
‡ We assumed that vaccine uptake followed a linear trend between 2006 and 2011. We calculated the constant and the slope of the line using
data from 2008 and 2011.
§ The probability of icteric infection among age group j is given by α0½1expðα1jα2 Þ.
|| The parameters of the Dirichlet distribution are as follows: D1 ¼ (780.58043, 5.01309, 0.00617, 0.00017, 0.00014), D2 ¼ (2960.87504, 70.72485,
0.00011, 0.00000, 0.00000), D3 ¼ (5625.35118, 179.22808, 0.01977, 0.00054, 0.00044), D4 ¼ (2792.46660, 72.77631, 1.29335, 0.03516, 0.02857), D5 ¼
(880.83558, 24.93756, 2.73634, 0.04583, 0.04469).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 5 8 – 3 6 7 363Indirect costs included the costs associated with the work loss
due to different health outcomes. These were estimated by
multiplying the days of work loss from an HAV disease outcome
by the labor force participation rate and daily wages of the
patients’ age group (Table 1).
Public health disease control costs are major components of
the economic burden of a hepatitis A outbreak that include
surveillance costs, immune globulin coordination and adminis-
tration costs, and public notiﬁcation costs [12,35]. We assumed
that the total cost of an outbreak scales up linearly with its size
and included a cost of $667 per reported symptomatic case of
hepatitis A [12]. All costs were converted to 2013 dollars using the
relevant component (medical care for direct costs and all items
for indirect costs) of the consumer price index [36]. Future costs
were discounted at a rate of 3% per year.
Utilities
We calculated quality-adjusted life-years (QALYs) by applying
utility weights to time spent in each health state. We assumed a
weight of 0.6819 for all outcomes related to hepatitis A, except
liver transplant [37]. For patients with liver transplant, we
assumed a weight of 0.73 for the remaining years of their lives
[38]. We assumed that quality-of-life weight for persons in all
other health states, including anicteric hepatitis A, is 1. To
account for variation in background quality of life by age, all
utility weights were multiplied by the age-speciﬁc US population
norm [39]. Future QALYs were discounted at 3% per year.
Implementation
The model was programmed in Mathematica 9.0 (Wolfram
Research, Inc., Champaign, IL). We used the built-in function
NDSolve to ﬁnd numerical solutions of the system of ordinary
differential equations. NDSolve solves differential equations by
using adaptive algorithms that include almost all the known
integration methods such as the fourth-order Runge-Kutta
method. The built-in function NMinimize was used for model
ﬁtting. We used Mathematica for all simulations, analysis, and
production of ﬁgures.Analyses
Base Case
We estimated expected health outcomes (total HAV infections,
symptomatic HAV infections, outpatient visits, hospitalizations,fulminant cases, number of liver transplants, deaths, QALYs) and
costs over a time horizon of 100 years.
Sensitivity Analyses
One-way sensitivity of the results was examined by changing the
base-case values of the following parameters: vaccination param-
eters (efﬁcacy, duration of protection, cost, coverage, and adher-
ence), cost parameters, quality-of-life weights, and discount rate.
In addition, we performed probabilistic sensitivity analysis
(PSA) using only a subset of parameters. We kept demographic
parameters, force of infection parameters, and some other natural
history parameters at their base-case values. Inputs related to
vaccine properties and uptake, clinical outcomes, cost, and quality-
of-life weights were included in a PSA (Table 1). The justiﬁcation for
the selection of the probability distribution function for each
parameter included in the PSA is provided in the Appendix in
Supplemental Materials. We used Latin hypercube sampling tech-
niques to generate 1000 random samples for use as inputs in
the simulations [40]. The results of PSA were summarized using the
mean of outcomes and presented using a scatter plot in the
incremental cost-effectiveness plane [41]. The plane summarizes
uncertainty in the results of the cost-effectiveness analysis by
showing the number of simulations for which a strategy is cost-
effective for a range of maximum monetary values that a decision
maker might be willing to pay for each QALY gained.
To further test the sensitivity of results to some inputs taking
extreme values, we conducted several scenario analyses for which
we made the following assumptions. First, we examined a scenario
in which herd protection/immunity effects are ignored. This entails
allowing the force of infection to change according to the prediction
of the model without vaccination. Thus, only the direct beneﬁts of
vaccination are conferred on persons receiving the vaccine. Second,
we assumed that adherence to the two-dose series is perfect. This
implies a high effective coverage with two-dose series among 1-
year-olds. Finally, we evaluated the cost-effectiveness of vaccina-
tion from the narrower health care perspective considering only
direct medical costs and excluding indirect costs.
Model Transparency and Validation
To facilitate independent review of the model as well as repli-
cation of our results, the model’s structure, all equations, inputs,
and outputs were made available in the Supplemental Technical
Report (see Supplementary Material found at http://dx.doi.org/10.
1016/j.jval.2015.02.004) [42]. We assessed the face validity of the
model by comparing its assumptions regarding the natural
history of HAV infection and disease with previously published
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 5 8 – 3 6 7364studies [21,43]. To ensure internal validity, several tests were
conducted (e.g., total outﬂow and inﬂow between compartments
are balanced and adding the number of persons in each compart-
ment is equivalent to the total population size). The predictive
validity of the model was evaluated by comparing model results
with epidemiologic data reported in the literature (see Appendix
in Supplemental Materials).Results
Base Case
Epidemiology results
The model predicted that universal childhood vaccination led to
a signiﬁcant reduction in the incidence of hepatitis A (Fig. 2). In
particular, the incidence of any hepatitis A infection under
regional vaccination declined from 103 per 100,000 in 2006 to 27
per 100,000 in 2020 under universal vaccination. Signiﬁcant
improvements in cumulative hepatitis A health outcomes in
the long run were predicted after the introduction of universal
vaccination (Table 2). For example, over a 100-year period, there
would be 33.9 million cases of hepatitis A infection under theTable 2 – Cumulative cases of hepatitis A disease in the U
of 1-y-olds over time (years after 2006).
Cumulative outcomes Regional vaccination through
10 y 50 y
Any infection (millions) 3.12 16.59
Anicteric infections (millions) 1.10 5.70
Icteric infections (millions) 2.03 10.89
Outpatient visits (millions) 1.96 10.53
Hospitalizations 56,195 301,348
Fulminant cases 6,567 39,059
Liver transplants 871 4,821
Deaths 2,115 13,748regional vaccination strategy and 7.9 million cases under the
universal vaccination strategy. Thus, switching from a policy of
regional vaccination to universal vaccination prevented 26.0 mil-
lion cases of hepatitis A. Universal vaccination led to a signiﬁcant
reduction in all the disease outcome measures included in the
model: outpatient visits, hospitalizations, fulminant hepatitis A,
liver transplants, and deaths (Table 2). Also, the cumulative
incremental beneﬁts of universal vaccination increased over time.
For example, relative to regional vaccination, universal vaccina-
tion prevented 28,152 hospitalizations over a 10-year period
compared with 478,122 hospitalizations over a 100-year period.
Cost-effectiveness results
The economic impact of the two strategies is presented in
Table 3. The results for costs and QALYs are presented on a
per-person basis. For example, vaccinating children under a
regional policy would cost $1.55 per person over 100 years
compared with $12.39 per person under a universal vaccination
strategy. Even though vaccination costs are higher under the
universal vaccination strategy, the total cost of universal vacci-
nation is lower due to lower direct and indirect medical costs
compared with regional policy. In particular, universal vaccina-
tion costs $33.48 per person over 100 years compared with a totalS population with regional and universal vaccination
Universal vaccination through
100 y 10 y 50 y 100 y
33.91 1.55 4.50 7.93
11.56 0.54 1.60 2.87
22.35 1.01 2.90 5.06
21.61 0.98 2.80 4.90
617,936 28,043 80,205 139,814
82,481 3,199 10,569 19,464
9,904 427 1,311 2,306
29,926 1,024 3,700 7,163
Table 3 – Cost-effectiveness analysis of a universal vaccination program of 1-y-olds over time compared with a
regional vaccination program.
Cumulative outcomes (per person) Regional vaccination through Universal vaccination through
10 y 50 y 100 y 10 y 50 y 100 y
Vaccination costs ($) 0.419 1.263 1.551 3.194 10.048 12.387
Disease costs ($) 10.905 34.762 43.294 6.303 12.287 13.933
Indirect costs ($) 6.178 19.730 24.505 3.164 6.242 7.159
Total costs ($) 17.502 55.754 69.350 12.661 28.577 33.480
QALYs (y) 7.498 22.617 27.776 7.498 22.618 27.777
ICER ($ per QALY) – – – Cost saving Cost saving Cost saving
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 5 8 – 3 6 7 365cost of $69.35 per person under a regional vaccination policy.
Also, universal vaccination generates higher discounted QALYs
per person than does a regional vaccination policy (Table 3).
Thus, universal vaccination is cost saving over a 100-year period,
with every $1 spent vaccinating a person through a universal
vaccination strategy as compared with a regional one resulting in
the society saving $2.7 in avoided disease costs and $1.6 in
avoided productivity losses and disease control costs. In fact,
universal vaccination was cost saving even when the time
horizon was assumed to be 10 years.Table 4 – Impact of herd protection effects of a
universal vaccination program of 1-y-olds in the US
population compared with a regional vaccination
program over 100 y.*
Incremental outcome
measures
Without herd
protection/
immunity
With herd
protection/
immunity
Cases prevented
Any infection (millions) 9.50 25.98
Icteric infections
(millions)
4.76 17.28Deterministic Sensitivity Analysis
The incremental cost of universal vaccination compared with a
regional vaccination policy was sensitive to variations in the
discount rate, vaccine uptake rate for the regional strategy,
outpatient days lost to work, outpatient cost, median weekly
earnings, hospitalization cost, public health cost of a reported
infection, cost of vaccine administration, cost of treating a
fulminant case, and vaccine efﬁcacy (see Appendix Table S4 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.02.004). Nonetheless, universal vaccination compared with a
regional vaccination policy remained cost saving over all the
ranges of parameter values considered. Universal vaccination
was also cost saving when we assumed that the adherence to the
two-dose series is perfect (see Appendix Table S5 in Supplemen-
tal Materials found at http://dx.doi.org/10.1016/j.jval.2015.02.004).
Because direct costs (vaccination þ disease costs) were lower,
universal vaccination compared with a regional vaccination
strategy was also cost saving from the health care perspective
(Table 3).Outpatient visits
(millions)
4.62 16.71
Hospitalizations 128,634 478,122
Fulminant cases 6,943 63,017
Liver
transplantations
1,140 7,598
Deaths 1,531 22,763
Additional costs ($ per person)
Vaccination costs 10.836 10.836
Disease costs –5.202 –29.361
Indirect costs –2.147 –17.346
Total costs 3.487 –35.870
Additional QALY (years per
person)
0.0002 0.0009
ICER ($ per QALY)* 21,223 Cost saving
ICER, incremental cost-effectiveness ratio; QALYs, quality-
adjusted life-years.
* ICER is not equal to total additional cost divided by total
additional QALYs because of rounding errors.Herd protection
The exclusion of herd protection/immunity in the model had a
signiﬁcant effect on results (Table 4). For example, by ignoring
herd protection 9.50 million cases of hepatitis A were avoided
using a universal vaccination policy instead of following a
regional policy for 100 years. In contrast, 25.98 million cases were
avoided if herd protection/immunity is taken into account. Also,
herd protection/immunity accounted for a signiﬁcant share of the
reduction in all the hepatitis A outcomes associated with vacci-
nation. For example, including herd protection in the analysis led
to a more than threefold increase in avoided outpatient visits,
hospitalizations, and fulminant cases (Table 4). These public
health beneﬁts of herd protection/immunity led to signiﬁcant
cost reduction and QALY gains. For example, ignoring herd
protection/immunity, when comparing universal vaccination
with regional vaccination, there is an additional $3.487 in cost
and 0.0002 in QALYs per person, for an incremental cost-
effectiveness ratio of $21,223 per QALY. With inclusion of herdprotection, however, universal vaccination was cost saving com-
pared with regional vaccination.Probabilistic Sensitivity Analysis
We performed a PSA using 1000 Monte Carlo simulations.
The results showed that the mean incremental total cost per
person of universal vaccination compared with a regional vacci-
nation policy was –$45.09 (95% conﬁdence interval –121.97 to –
11.21). The corresponding values for QALYs were 0.00061 (95%
conﬁdence interval 0.00053–0.00069). The median incremental
cost and QALY was –$37.23 and 0.00061 years, respectively. The
incremental cost-effectiveness plane showed that all incremental
cost-QALY pairs fall in the southeast quadrant, indicating that
the universal vaccination policy is less costly and more effective
than the regional vaccination policy in all the 1000 simulations
(Fig. 3).
–210
–180
–150
–120
–90
–60
–30
0
0 0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007 0.0008
In
cr
em
en
ta
l T
ot
al
 C
os
t p
er
 p
er
so
n 
($
)
Incremental QALYs per person (years)
Fig. 3 – Scatter plot of estimated joint density of incremental
total costs and QALYs per person of universal compared
with regional vaccination. QALY, quality-adjusted life-year.
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We developed a dynamic model to evaluate the cost-
effectiveness of universal hepatitis A vaccination of children in
the United States. Previous cost-effectiveness models of hepatitis
A vaccine in the United States used a cohort model. Although
cohort models showed the HAV vaccine to be cost-effective, they
do not estimate herd protection effects of vaccination on the
disease costs and health outcomes. To our knowledge, this is the
ﬁrst cost-effectiveness evaluation of hepatitis A vaccination in
the United States that used a dynamic modeling approach with
herd protection effects. In the base case, universal vaccination
was cost saving compared with a regional vaccination program.
Universal vaccination also led to signiﬁcant reductions in HAV
cases and associated morbidity and mortality. The model also
showed that herd protection effects played an important role in
reducing HAV disease incidence and associated costs. In partic-
ular, the impact of herd protection on the cost-effectiveness ratio
was profound. When we excluded herd protection effects, the
incremental cost-effectiveness ratio changed from cost saving to
$21,223 per QALY.
Some previous studies modeled changes in HAV incidence
over time during prevaccination as exogenous exponential decay
functions in time [3,12]. For example, Rein et al. [12] assumed that
the incidence of hepatitis A would decline at a constant annual
rate of 1.4% after 1990. To our knowledge, this is the ﬁrst study
that predicted endogenous changes in the incidence of hepatitis
A during the prevaccine era in response to external effects on the
force of infection (e.g., improvement in public infrastructure and
sanitation). One other key difference between the model in this
study and previous models is the inclusion of maternal anti-
bodies. Several studies estimated seroprevalence at birth at 100%
in many developed and developing countries [44,53,54]. A recent
modeling study using data on infants from Nicaragua found the
median time when antibodies would fall below the level of
seroprotection (assumed 10 mIU/ml) was 11.1 months [54].
Because maternally derived antibodies persist for a relatively
extended period of time in a signiﬁcant proportion of infants, it is
important to capture their inﬂuence on population-level immun-
ity when assessing the impact of hepatitis A vaccination.
This study has several limitations. First, our ﬁndings were
based on a modeling exercise, rather than real-world data.
Because models are simpliﬁcations of reality, they have inherent
limitations (e.g., may not accurately represent a very important
real-world event). Second, because of lack of data to informmodel’s parameters (e.g., infectivity and contact patterns), we
made several simplifying assumptions regarding disease trans-
mission (e.g., proportionate mixing) and inferred the values of
some of these parameters by ﬁtting the model to historical data.
We also assumed that several parameter values will stay con-
stant during the simulation period. This may be a reasonable
assumption for some, but unrealistic for others. For example,
vaccine coverage, compliance with the two-dose vaccine series,
and contribution of international travel to infection may change
in the future. Third, because not all cases of HAV infection are
reported to public health authorities, we adjusted the reported
incidence data upward to account for underreporting. Fourth,
values of parameters were obtained through a synthesis of the
literature with some uncertainties around the values of some
parameters. Finally, we did not include the cost or disutility of
any adverse events. Because there are no serious adverse events
associated with the administration of the vaccine, and most
commonly reported adverse events (e.g., injection site pain,
erythema, or swelling) are generally mild and self-limited, it is
unlikely that the inclusion of adverse events will have any
material effects on the results.
Although the ACIP recommended routine hepatitis A vacci-
nation for all children in the United States in 2006, the uptake of
the two-dose hepatitis A vaccine is well below the coverage rates
of other pediatric and adolescent vaccines [9]. Even though the
HAV disease burden in the United States is at its all-time low,
there still remains a substantial burden of disease from hepatitis
A. The results from the analysis presented here show that it may
be a sound economic strategy to increase hepatitis A vaccine
coverage given that the universal vaccination is cost saving from
both a payer and a societal perspective.
Source of ﬁnancial support: Merck Sharp & Dohme Corp., a
subsidiary of Merck &Co., Inc., Whitehouse Station, NJ, sponsored
the study.Supplemental Materials
Supplemental material accompanying this article can be found in
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jval.2015.02.004 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).
R E F E R E N C E S[1] Jacobsen KH. The Global Prevalence of Hepatitis A Virus Infection and
Susceptibility: A Systematic Review. Geneva, Switzerland: World Health
Organization, 2009.
[2] Center for Disease Control and Prevention. Summary of notiﬁable
diseases—United States, 1995. MMWR Wkly Rep 2005;44:1–87.
[3] Armstrong GL, Bell BP. Hepatitis A virus infections in the United States:
model-based estimates and implications for childhood immunization.
Pediatrics 2002;109:839–45.
[4] Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A
vaccine. N Engl J Med 2004;350:476–81.
[5] Dalton CB, Haddix A, Hoffman RE, Mast EE. The cost of a food-borne
outbreak of hepatitis A in Denver, Colorado. Arch Intern Med
1996;156:1013–6.
[6] Eisenberg DF, Burstin SJ, Fang C, Misurski DA. Health care utilization
and associated costs of hepatitis A in adults in a US commercially
insured population. Health Outcomes Res Med 2012;3:e91–101.
[7] Luyten J, Beutels P. Costing infectious disease outbreaks for economic
evaluation: a review for hepatitis A. Pharmacoeconomics
2009;27:379–89.
[8] Advisory Committee on Immunization Practices, Fiore AE, Wasley A,
Bell BP. Prevention of hepatitis A through active or passive
immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1–23.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 5 8 – 3 6 7 367[9] Centers for Disease Control and Prevention. Estimated vaccination
coverage with individual vaccines and selected vaccination series
before 24 months of age by state and local area, US National
Immunization Survey, Q1/2011-Q4/2011. Available from: http://www.
cdc.gov/vaccines/imz-managers/coverage/nis/child/tables/11/
tab09_24mo_iap_2011.pdf. [Accessed March 12, 2015].
[10] Centers for Disease Control and Prevention. Hepatitis A factors for
health care professionals. Available from: http://www.cdc.gov/
hepatitis/hav/havfaq.htm. [Accessed September 9, 2013].
[11] Anonychuk AM, Tricco AC, Bauch CT, et al. Cost-effectiveness analyses
of hepatitis A vaccine: a systematic review to explore the effect of
methodological quality on the economic attractiveness of vaccination
strategies. Pharmacoeconomics 2008;26:17–32.
[12] Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine
childhood vaccination for hepatitis A in the United States. Pediatrics
2007;119:e12–21.
[13] Rein DB, Hicks KA, Wirth KE, et al. The economics of routine childhood
hepatitis A immunization in the United States: the impact of herd
immunity. Pediatrics 2007;119:22–9.
[14] Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of
vaccination programmes: a dynamic perspective. Stat Med
1999;18:3263–82.
[15] Pitman R, Fisman D, Zaric GS, et al. ISPOR-SMDM Modeling Good
Research Practices Task Force. Dynamic transmission modeling: a
report of the ISPOR-SMDM Modeling Good Research Practices Task
Force Working Group–5. Value Health 2012;15:828–34.
[16] Hethcote HW. An age-structured model of pertussis transmission.
Math Biosci 1997;145:89–136.
[17] Arias E, Curtin LR, Wei R, Anderson RN. United States decennial life
tables for 1999–2001, United States life tables. Natl Vital Stat Rep
2008;57:1–36.
[18] U.S. Census Bureau. Intercensal estimates of the resident population by
sex and age for the United States: April 1, 2000 to July 1, 2010 (US-
EST00INT-01). Table 1, Sept, 2011. Available from: http://www.census.
gov/popest/data/intercensal/national/nat2010.html, [Accessed
February 27, 2013].
[19] Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A
epidemiology in the United States—implications for vaccination
strategies. J Infect Dis 1998;178:1579–84.
[20] Klevens RM, Miller JT, Iqbal K, et al. The evolving epidemiology of
hepatitis A in the United States: incidence and molecular epidemiology
from population-based surveillance, 2005-2007. Arch Intern Med
2010;170:1811–8.
[21] Amariei R, Willms AR, Bauch CT. The United States and Canada as a
coupled epidemiological system: an example from hepatitis A. BMC
Infect Dis 2008;8:23.
[22] Second National Health and Nutrition Examination Survey, (NHANES
II), 1976-1980. Hyattsville, MD: Centers for Disease Control and
Prevention, National Center for Health Statistics, U.S. Department of
Health and Human Services (DHHS), 1981.
[23] Third National Health and Nutrition Examination Survey, 1988-1994,
NHANES III Laboratory Data File. Public Use Data File Documentation
Number 76200. Hyattsville, MD: Centers for Disease Control and
Prevention, National Center for Health Statistics, U.S. Department of
Health and Human Services (DHHS), 1996.
[24] Centers for Disease Control and Prevention. National Notiﬁable
Diseases Surveillance System (NNDSS). Atlanta, GA: Centers for Disease
Control and Prevention, Division of Notiﬁable Diseases and Healthcare
Information, 1999.
[25] Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-
inactivated hepatitis A vaccine in healthy children. N Engl J Med
1992;327:453–7.
[26] Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A
vaccines: a systematic review. Vaccine 2012;31:3–11.
[27] Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from
clinical hepatitis A disease after vaccination with VAQTA. J Med Virol
1996;49:235–41.
[28] Zhou F, Shefer A, Weinbaum C, et al. Impact of hepatitis A vaccination
on health care utilization in the United States, 1996–2004. Vaccine
2007;25:3581–7.
[29] Centers for Disease Control and Prevention. National, state, and local
area vaccination coverage among children aged 19-35 months—United
States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:689–96.
[30] McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental
per patient per year cost associated with chronic hepatitis C virus andassociated liver complications in the United States: a managed care
perspective. J Manag Care Pharm 2011;17:531–46.
[31] Berge JJ, Drennan DP, Jacobs RJ, et al. The cost of hepatitis A infections
in American adolescents and adults in 1997. Hepatology
2000;31:469–73.
[32] Centers for Disease Control and Prevention. Pediatric/VFC vaccine price
list. Available from: http://www.cdc.gov/vaccines/programs/vfc/
awardees/vaccine-management/price-list/. [Accessed September 9,
2013].
[33] IMS. Deﬁned daily doses (DDD). Unpublished data for the period
January 2002 -July2013. Danbury, CT: IMS Institute for Healthcare
Informatics, IMS Health, 2013.
[34] Glazner JE, Beaty B, Berman S. Cost of vaccine administration among
pediatric practices. Pediatrics 2009;124(Suppl. 5):S492–8.
[35] Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children,
adolescents, and adults. Hepatology 2003;37:44–51.
[36] U.S. Bureau of Labor Statistics. Consumer price indexes. Available from:
www.bls.gov/cpi/home.htm. [Accessed October 17, 2013].
[37] Luyten J, Marais C, Hens N, et al. Imputing QALYs from single time
point health state descriptions on the EQ-5D and the SF-6D: a
comparison of methods for hepatitis A patients. Value Health
2011;14:282–90.
[38] Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities
and quality of life in hepatitis C patients. Am J Gastroenterol
2003;98:630–8.
[39] Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally
representative values for the noninstitutionalized US adult population
for 7 health-related quality-of-life scores. Med Decis Making
2006;26:391–400.
[40] Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of
complex models of disease transmission: an HIV model, as an example.
Int Stat Rev 1994;62:229–43.
[41] Black WC. The CE plane: a graphic representation of cost-effectiveness.
Med Decis Making 1990;10:212–4.
[42] Eddy DM, Hollingworth W, Caro JJ, et al. ISPOR-SMDM Modeling Good
Research Practices Task Force. Model transparency and validation: a
report of the ISPOR-SMDM Modeling Good Research Practices Task
Force-7. Value Health 2012;15:843–50.
[43] Bauch CT, Anonychuk AM, Pham BZ, et al. Cost-utility of universal
hepatitis A vaccination in Canada. Vaccine 2007;25:8536–48.
[44] Linder N, Karetnyi Y, Gidony Y, et al. Decline of hepatitis A antibodies
during the ﬁrst 7 months of life in full-term and preterm infants.
Infection 1999;27:128–31.
[45] Leach CT. Hepatitis A in the United States. Pediatr Infect Dis J
2004;23:551–2.
[46] Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines.
Hepatology 2006;43(Suppl. 1):S164–72.
[47] Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis
A immunization in the United States, 1995–2001. Vaccine 2004;22:4342–50.
[48] Wolfe RA, Merion RM, Roys EC, Port FK. Trends in organ donation and
transplantation in the United States, 1998–2007. Am J Transplant 2009;9
(Pt 2):869–78.
[49] Huda A, Newcomer R, Harrington C, et al. High rate of unemployment
after liver transplantation: analysis of the United Network for Organ
Sharing database. Liver Transpl 2012;18:89–99.
[50] U.S. Bureau of Labor Statistics. Labor force statistics from the Current
Population Survey: employment status of the civilian noninstitutional
population by age, sex, and race. Available from: http://www.bls.gov/
cps/cpsaat03.htm. [Accessed October 28, 2013].
[51] U.S. Bureau of Labor Statistics. Table 3: median usual weekly earnings
of full-time wage and salary workers by age, race, Hispanic or Latino
ethnicity, and sex, second quarter 2013 averages, not seasonally
adjusted. 2013. Available from: http://www.bls.gov/news.release/
wkyeng.t03.htm. [Accessed October 28, 2013].
[52] U.S. Bureau of Labor Statistics. Table 5: quartiles and selected deciles of
usual weekly earnings of full-time wage and salary workers by selected
characteristics, second quarter 2013 averages, not seasonally adjusted.
2013. Available from: http://www.bls.gov/news.release/wkyeng.t05.
htm. [Accessed October 28, 2013].
[53] Derya A, Necmi A, Emre A, Akgün Y. Decline of maternal hepatitis A
antibodies during the ﬁrst 2 years of life in infants born in Turkey. Am J
Trop Med Hyg 2005;73:457–9.
[54] Brinkhof MW, Mayorga O, Bock J, et al. Kinetics of maternally acquired
anti-hepatitis A antibodies: prediction of waning based on maternal or
cord blood antibody levels. Vaccine 2013;31:1490–5.
